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Abstract: The functional physicochemical properties of nicotine (NIC)-loaded composite freeze-dried
wafers and solvent-evaporated films comprising hydroxypropylmethylcellulose (HPMC) and
sodium alginate (SA), stabilized with magnesium aluminium silicate (MAS), have been reported.
The formulations were characterized for swelling capacity, mucoadhesion, in vitro drug dissolution
properties in simulated saliva (SS) and PBS at pH 6.8, and ex vivo and in vitro permeation using
pig buccal mucosa membrane and EpiOralTM buccal tissue culture, respectively; finally, the cell
viability of the EpiOralTM tissues after contact with the NIC-loaded formulations was investigated
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the functional
characteristics compared with those of commercially available NIC strips. Swelling and NIC release
from the HPMC–SA wafers were more prolonged (30 min) compared to the commercially available
NIC strips which disintegrated rapidly and released the drug within 5 min. Generally, swelling,
mucoadhesion, and drug release was faster in PBS than in SS, and the presence of MAS was essential
for maintaining a high dose recovery compared to non-MAS formulations and commercial NIC
strips, which showed lower percentage of NIC content, possibly due to evaporation during analysis.
Permeation studies showed that the NIC released was able to cross both porcine buccal membrane and
the EpiOralTM buccal tissue, with the latter showing higher permeation flux for all the formulations
tested. All the NIC-loaded, MAS-stabilized formulations showed high tissue viability, with values
above 80%, showing their great potential for use as buccal delivery platforms for NIC replacement
therapy to aid smoking cessation.
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1. Introduction
Life threatening diseases such as lung cancer, chronic obstructive pulmonary disease,
and cardiovascular diseases (e.g., coronary heart disease and stroke) are usually associated with
cigarette smoking (U.S. Department of Health and Human Services, 2014). However, these risks are
significantly decreased when smoking is curtailed, depending on factors such as age, sex, physiology,
and smoking frequency. For example, the life expectancy of a smoker after cessation at 35 years could
increase by 20–24% in men and 17–22% in women. However, the life expectancy of a smoker after
cessation at 65 years could increase by just 2–3% in men and 4–5% in women. It is therefore more
beneficial to quit smoking as early as possible [1]. An active smoker of tobacco draws in smoke known
as mainstream smoke which comprises 8% tar and 92% gaseous components, while the side-stream
released at the burning tail of a lit cigarette contains a higher proportion of poisonous components such
as nitric oxide and carbon monoxide [2], leading to risks of severe heart disease in non-smokers [3].
Over the years, there have been various initiatives aimed at smoking cessation due to the health
risks of tobacco, including the tobacco-free initiative (TFI) approved by the WHO. However, sudden
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cessation can lead to several withdrawal symptoms, including irritability, sleeplessness, and continuous
cigarette craving [4]. The withdrawal symptoms can last between 2 and 12 h [5,6] and have been
managed using nicotine (NIC) replacement therapies (NRTs). NIC cannot be developed as an oral
pill due to its susceptibility to first-pass metabolism in the liver [7], and efforts have been made to
develop alternative drug delivery systems [8] for NRT. These include chewing gums, lozenges, mouth
sprays, nasal sprays, transdermal patches (e.g., Nicorette), and oral films such as NiQuitin® strips [9].
Though these can achieve successful quitting of smoking, they have their limitations, and therefore
novel delivery systems are required. The transdermal patch provides slow and sustained NIC release;
however, it does not match the fast delivery of NIC from cigarette smoking [10]. Itching, oedema, and
erythema have also been associated with transdermal patches [11]. NIC chewing gum can sometimes
result in slow onset and prolonged plasma NIC levels which cannot be matched with the rapid
pharmacological effect and high maximum arterial NIC levels required for relief [12]. Oral sprays
allow rapid NIC absorption, but they require constant administration, and hence the bioavailability
at the therapeutic level is not sustained. NRT strips such as NiQuitin® deals with the challenge
of chewing gum for people with dental issues or who wear dentures. However, they still face the
limitation of lower absorption of NIC due to the effect of eventual swallowing [13]. Electronic NIC
delivery systems (ENDS) can be misused as a substitute for cigarettes, encouraging significant numbers
of smokers not to quit smoking altogether [14]. Furthermore, a recent study has demonstrated the
presence of low concentrations of free radicals in e-cigarettes, which can possibly cause harm to human
cells [15]. Lermer and co-workers also demonstrated the presence of potential cytotoxic metals (such
as copper) and oxidants (e.g., perhydroxyl radical (HO2·)) normally associated with conventional
cigarette, in e-cigarettes [16].
In comparison to transdermal routes, the buccal mucosa demonstrates better permeability since
human buccal mucosa is composed mostly of non-keratinized cells [17,18]. The ready permeability
of NIC across the buccal mucosa has been attributed to its high solubility in both water and organic
solvents (LogP of 1.17) and its low molecular weight (162.2 g/mol) [19,20]. The permeability of
NIC species depends on pH; however, all species of NIC can readily permeate mucosal membranes
with higher permeation for un-ionized species than ionized species [21]. Porcine buccal mucosa has
similar morphology and permeation to the human buccal mucosa in terms of non-keratinized cells
and enzymatic activities [17], as reported for drugs such as naratriptan [22], NIC [23], buspirone [24],
omeprazole [25,26], and doxepin [18]. Other buccal mucosa models such as sheep buccal mucosa have
been reported in permeation studies [27,28]. EpiOralTM buccal tissue comprises typical human-derived
epithelial cells developed by MatTeK (MatTek Corporation, Ashland, MA, USA) and has recently
been engineered and commercialized for better controlled permeation studies due to uniform and
reproducible in vivo-like morphology and growth characteristics (www.mattek.com (accessed 17
October 2016)). Several researchers have utilized EpiOralTM buccal tissue as a model in permeation
studies [28–30].
The aim of this study was to investigate the functional physicochemical characteristics of
clay-stabilized NIC within composite wafers and films prepared from hydroxypropylmethylcellulose
(HPMC) and sodium alginate (SA) compared with commercially available NIC-loaded strips. Further,
the permeation of NIC released from the composite HPMC–SA wafers and films using porcine
buccal tissue and a human equivalent EpiOralTM buccal tissue as well as the tissue viability of the
EpiOralTM tissue after coming in contact with the NIC-loaded wafers and films was investigated using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
2. Materials and Methods
2.1. Materials
Hydroxypropylmethylcellulose (HPMC; Methocel K100 Premium LV) was a gift from Colorcon
Limited (Dartford, UK), and magnesium aluminium silicate (MAS) was a gift from R.T. Vanderbilt
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Company Inc. (Norwalk, CT, USA). Sodium hydroxide, potassium dihydrogen phosphate, and gelatine
were purchased from Fluka Analytical (Buchs, Switzerland). Nicotine (liquid form), sodium alginate
(SA; molecular weight 120,000–190,000 g/mol, mannuronate/guluronate ratio 1.56), submaxillary
mucin from porcine stomach, PBS tablets (pH 7.4), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), Krebs–Ringer bicarbonate buffer, and dimethyl sulfoxide (DMSO) were all obtained
from Sigma Aldrich (Dorset, UK). Sodium acetate, trimethylamine, and glycerol (GLY) were purchased
from Fisher Scientific (Loughborough, UK). Commercially available NIC-loaded strips (NiQuitin®) was
purchased from a local pharmacy (Gillingham, Kent). Calcium chloride dehydrate, sodium chloride,
sodium phosphate dibasic, magnesium chloride hexahydrate, potassium carbonate hemihydrate,
sodium phosphate monobasic monohydrate, sodium acetate, and trimethylamine were all purchased
from Fisher Scientific (Loughborough, UK). The EpiOralTM buccal tissue kit (ORL-200) was purchased
from MatTek Corporation (Ashland, MA, USA).
Preparation of Simulated Saliva
Simulated saliva was prepared using the formula summarized in Table 1.
Table 1. Simulated saliva (SS) compositions used in this study [31].
Composition Concentration (g/L)
Calcium chloride dehydrate 0.228
Sodium chloride 1.017
Sodium phosphate dibasic 0.204
Magnesium chloride hexahydrate 0.061
Potassium carbonate hemihydrate 0.603
Sodium phosphate monobasic monohydrate 0.273
Submaxillary mucin 1.00
pH 6.8
2.2. Selected Optimized Formulations
The following formulations in Table 2 were selected for the investigation of the effect of PBS and
SS (pH 6.8; ionic strength, 0.04) on swelling and in vitro drug dissolution characteristics. The MAS and
non-MAS formulations were prepared as previously described, respectively [32,33].
Table 2. Composite HPMC–SA wafers and films used for this study. NIC: nicotine;
HPMC: hydroxypropylmethylcellulose; SA: sodium alginate; GLY: glycerol; MAS: magnesium
aluminium silicate.
NIC-Loaded Formulations HPMC(% w/v)
SA
(% w/v)
GLY
(% w/v)
MAS
(% w/v)
NIC
(g)
MAS wafer 1.25 0.75 - 0.25 0.20
MAS film 1.25 0.75 2.00 0.25 0.20
Non-MAS wafer 1.25 0.75 - - 0.20
2.3. Swelling and In Vitro Mucoadhesion Studies
The swelling capacities of wafers and films, as well as commercially available NIC-loaded strips,
were determined by immersing each formulation into 5 mL of PBS (pH 6.8) or SS (pH 6.8; ionic
strength, 0.04 M). The percentage swelling index was investigated by recording change in weight
at time intervals of 2 min up to 30 min. For every time point, the medium was carefully removed
to obtain an accurate weight of the sample and replaced with fresh medium. Three replicates were
performed for each sample and swelling index (%) was calculated using Equation [34].
Swelling index =
Ws−Wd
Wd
× 100 (1)
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where Wd = dry weight of polymeric wafer/film, Ws = weight of wafer/film after swelling.
Adhesion test was performed on the wafers and films using a TA. HD plus Texture Analyzer
(Stable Micro Systems, Surry, UK) in tensile mode and fitted with a 5-kg load cell. Films were cut
to dimensions matching the mathematical area of wafers (a circle with diameter = 15.5 mm) and
attached to an adhesive probe (75 mm diameter) of the TA instrument using double-sided adhesive
tape. Gelatine gel (6.67% (w/v)) was prepared by dissolving gelatine powder in water at 70 ◦C, poured
into a Petri dish (86 mm diameter), and placed in a fridge overnight to set into a solid gel to represent
the buccal mucosa surface. Mucin solution (2% w/v) was prepared by dissolving mucin powder in
SS and 0.5 mL evenly spread on the surface of the set gelatine gel to simulate the buccal mucosa.
The probe with film or wafer attached was lowered to make contact with the model buccal mucosa
surface with an applied force of 1.0N and detached after a contact time of 60 s. Mucoadhesive strength
was determined by the maximum adhesive force (Fmax) required to detach the sample from the model
buccal surface, work of adhesion was determined by the area under the force-distance curve, while
cohesiveness represents the distance the wafers/films travelled till they detached from the model
buccal surface.
Finally, the swelling capacities and mucoadhesion profiles of the commercial NIC-loaded strip
were compared to those of the formulated composite HPMC–SA wafers and films.
2.4. In Vitro Drug Dissolution Studies
In vitro drug dissolution of the wafers and films was performed with the help of a Franz-diffusion
cell apparatus. The receptor compartment was filled with 8 mL of PBS or SS (pH 6.8) with a mesh
on the receptor surface. The donor and receptor compartments were sealed with paraffin, to limit
evaporation and held together by a pinch clamp. The system was placed on a water bath at 37 ◦C
with magnetic stirring at approximately 200 rpm. The samples were weighed and placed on the mesh
between the donor and receptor compartments. At predetermined time intervals, 0.5-mL aliquots
of the dissolution media were withdrawn using a 1-mL syringe, filtered through a 0.45-µm cellulose
acetate membrane, transferred into glass vials, and analysed using HPLC. The aliquots withdrawn at
each time point, was replaced with fresh buffer solution, in order to maintain a constant volume of
dissolution media. The percentage drug released from the formulations was calculated and plotted
against time (n = 3). Further, the in vitro drug dissolution of the commercial strip was performed
with the protocol described above but with only SS and compared to the drug release profiles of the
HPMC–SA wafers and films.
2.5. Comparison of Release Profiles using Difference and Similarity Factors
The equations of Moore and Flanner were adopted in the calculation of the difference (f 1) and
the similarity (f 2) factors in comparing the release profiles of the wafers and films in SS and PBS as
well as between the wafers, films and commercial NIC-loaded strips. The difference factor value (f 1)
measures the percent error between two curves over all time points, while the similarity (f 2) factors
value is a logarithmic transformation of the sum-squared error of differences between the test Tj and
reference products Rj over all time points [35]. The difference (f 1) and the similarity (f 2) factors were
calculated using Equations (2) and (3) below:
f1 =
∑nj=1
∣∣Rj − Tj∣∣
∑nj=1 Rj
× 100 (2)
f2 = 50× log{(1 +
(
1
n
) n
∑
j=1
∣∣Rj − Tj∣∣2)} × 100 (3)
Pharmaceutics 2019, 11, 104 5 of 20
The drug release profiles are considered similar if the f 1 values is close to 0 and the f 2 values is
close to 100 or if f 1 is lower than 15 and f 2 value is higher than 50. According to FDA recommendations,
a similarity is declared for two drug release profiles if f 2 is between 50 and 100 [36–38].
2.6. Drug Content (% Loading/Recovery)
The content of NIC in commercial strip was assayed and the results were compared to that
obtained for the HPMC–SA wafers and films. The content of NIC in all the samples (n = 3) was assayed,
by accurately weighing each sample and dissolving in 10 mL of distilled water. The resulting solution
was collected into a syringe, filtered through a 0.45-µm cellulose acetate membrane, transferred
into sample vials, placed in the HPLC sample chamber, and analysed using HPLC conditions as
described below.
HPLC Analysis
NIC was analysed by HPLC using an Agilent 1200 HPLC instrument (Agilent Technologies,
Cheshire, UK) with an auto sampler. The stationary phase used was a C-18 reverse-phase column,
4.6 × 250 mm (Phenomenex, Cheshire, UK). Sodium acetate solution, methanol and trimethylamine,
(88:12:0.5 v/v) were used as mobile phase with pH adjusted to 4.2 using glacial acetic acid, at a
flow rate of 1 mL/min and UV detection at 259 nm [39]. The retention time of NIC was detected at
approximately 4.5 min. A calibration curve was plotted from NIC standards ranging from 40 µg/mL
to 400 µg/mL (R2 = 0.9994).
2.7. Permeation and Tissue Viability Studies
The HPMC–SA wafers and films were investigated for NIC permeation across porcine and
EpiOralTM buccal tissues. Non-treated EpiOralTM tissue was used as a negative control in MTT assay
for tissue integrity (viability) studies.
2.7.1. Ex Vivo Buccal Permeation Studies
Ex vivo buccal permeation studies of NIC released from wafers (MAS and non-MAS wafers) and
films (MAS films) were carried out using Franz diffusion cell with a diffusional surface area of 0.6 cm2.
Fresh porcine buccal tissue was obtained from a local slaughterhouse (Kent, UK) and was immediately
stored in a container containing Krebs–Ringer bicarbonate buffer (modified with sodium bicarbonate)
and used within 2 h of slaughter [28,40]. The tissues were trimmed with a scalpel to a thickness of
1–3 mm and washed with physiological PBS (pH 6.8) at 37 ◦C. Membranes were mounted on a Franz
diffusion cell between the donor and the receiver (8 mL of 0.01 M PBS; pH 6.8) compartments with the
epithelial side facing the donor compartment. The receiver compartment was allowed to equilibrate at
37 ◦C for 30 min while stirring at 200–400 rpm. After the equilibration period, 0.5 mL of 0.01 M PBS
were poured into the donor compartment and 20–30 mg of optimized wafers or films were placed in
the donor compartment with the mucoadhesive layer in contact with the epithelial surface. The donor
and the receiver chambers were held together tightly with a cell clamp and sealed with parafilm to
limit evaporation. Samples (0.5 mL) were collected at predetermined time intervals from the port of
the receiver compartment and replaced with the same amount of PBS in order to maintain a steady
volume for 4 h. The collected samples were analysed using HPLC. Permeation flux (J) was determined
using Equation (4).
J =
dQ
dt
.
1
A
, (4)
J = steady state flux; dQ/dt = amount of drug permeated; A = effective diffusion area.
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2.7.2. In Vitro Buccal Permeation Studies (EpiOralTM Buccal Tissue)
EpiOralTM assay medium (MatTek, Ashland, MA, USA) was pre-warmed to 37 ◦C for 30 min.
Using a sterile technique, 0.3 mL/well of EpiOralTM assay medium were pipetted into four wells of a
24-well plate and labelled as 1 h equilibration. The remaining wells were labelled as 0.5, 1, 2, 3, and 4 h.
The EpiOralTM samples were transferred into the 1-h equilibration wells containing the pre-warmed
assay medium and placed in a 37 ◦C, 5% CO2 incubator for 1 h. After 1 h equilibration, the EpiOralTM
was transferred into the 0.5-h labelled well, treated with 0.5 mL donor solution (0.01 M PBS) into
which 15 mg of wafers and/or film were added with the mucoadhesive layer in contact with the apical
surface of the EpiOralTM buccal tissue, and returned to the incubator. After the elapsed time point
(0.5 h) the tissue was moved to the next time point (i.e., 1, 2, 3, and 4 h) till the total elapsed time (4 h).
Then, 50 µL of the receiver fluid were collected at predetermined time intervals and transferred to a
vial for HPLC analysis. Permeation flux (J) was determined using Equation (4).
2.7.3. Permeation Correlation between Porcine and EpiOralTM Buccal Tissues.
The permeability of NIC across the porcine buccal tissue and EpiOralTM engineered human buccal
tissue epithelium was further investigated to determine the correlation using a correlation curve of
EpiOralTM cumulative permeation against the porcine cumulative permeation curve of wafers and
film. Linear regression (R2) obtained from the curve of film and wafers was compared.
2.7.4. Tissue Viability (MTT Assay) of EpiOralTM Tissues after Permeation Studies
Following the EpiOralTM permeation studies, the tissue inserts used were transferred into a
24-well plate filled with MTT solution (0.3 mL) dissolved in PBS (5 mg/mL) and incubated for 3 h.
After incubation, the MTT was gently extracted from all well plates and the cultures were extracted
in 2 mL of DMSO for 2 h with gentle shaking (120 rpm). The aliquots (n = 3) of the extracts (200 µL)
were placed in a 96-well plate and the absorbance of the extracted (purple-coloured) formazan was
determined using a Multiskan microplate photometer at 540 nm. The viable cells had the greatest
amount of MTT reduction and hence the highest absorbance values. Relative cell viability was
calculated for each tissue used during permeation as a percentage of the mean negative control tissues
(n = 3). The average percentage cell viability of optimized wafers and films was plotted using the
non-treated tissues as negative control, which have 100% viability.
2.8. Statistical Analysis
Statistical analysis was performed using student t-test and/or one-way ANOVA to compare the
results. The results were expressed as mean ± standard deviation and significant differences were
determined at a level of p < 0.05.
3. Results
3.1. Swelling Studies
3.1.1. HPMC/SA Wafers and Films
Figure 1 shows the swelling profiles (% swelling index against time) of the wafers (MAS wafer
and non-MAS wafer) and films (MAS film) in SS and PBS media. The wafers (i.e., MAS and
non-MAS wafers) in general demonstrated higher swelling index in both SS (maximum swelling
index; 1178 ± 221%) and PBS (maximum swelling index; 897 ± 26%) than the films (swelling index of
600 ± 243%, 672 ± 10% in PBS and SS maximum, respectively). There was a difference in the swelling
profile of all formulations (both wafers and films) between SS and PBS medium. MAS wafer showed
a statistically significant difference (p < 0.05) between SS and PBS swelling profiles, while MAS film
and non-MAS wafer showed no statistically significant difference (p > 0.05 and p > 0.05, respectively).
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However, the structural integrity of MAS films and non-MAS wafers was observed to decrease after
10 min.
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3.2. In Vitro Mucoadhesion
3.2.1. HPMC/SA Wafers and Films
Figure 3 shows the adhesive properties (PAF, TWA, and cohesiveness) of wafers and films.
The peak adhesion force (PAF) or Fmax of the wafers and films were higher in PBS compared to SS.
In PBS, the maximum value of 2.05 ± 0.25 N was observed in MAS film compared to MAS wafers and
non-MAS wafers, with a PAF of 0.23 ± 0.003 N and 1.29 ± 0.22 N, respectively. In SS, the maximum
value decreased but was also observed to be higher in MAS film (0.37 ± 0.08 N) compared to MAS
wafers (0.23 ± 0.03 N) and non-MAS wafers (0.17 ± 0.03 N). TWA and cohesiveness also followed
a similar trend as PAF, with a decrease in TWA and cohesiveness in SS. However, the maximum
cohesiveness was observed in MAS wafers (9.96 ± 0.71 N) compared to MAS film (2.07 ± 0.45 N) and
non-MAS wafers (1.92 ± 0.51 N).
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3.3. In Vitro Drug Dissolution
3.3.1. HPMC–SA Wafers and Films
Figure 5 shows the drug dissolution profiles of NIC-loaded wafers and films in SS and PBS.
The dissolution profiles of wafers (MAS wafer and non-MAS wafer) showed a rapid drug release
with about 80–100% of NIC released within 60 min in PBS, while the MAS film demonstrated a more
sustained release profile as NIC was gradually released from the polymeric matrix in PBS. On the other
hand, NIC release from wafers and films in the presence SS appear to demonstrate a much slower NIC
release profile for all wafers and films within th first 2 h of releas , though a much longer release
period could have shown much more release of the drug. The NIC release from MAS wafer, MAS film,
and non-MAS wafer in SS and PBS demonstrated a statisticall significant difference (p < 0.05, p < 0.05
and p < 0.05, respectively).
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3.3.2. Commercial Strip (NiQuitin®) versus Optimized Wafers and Films in SS
Figure 6 compares the in vitro drug dissolution profiles of NiQuitin® commercial strip and
optimized formulations (i.e., MAS wafer, MAS film and non-MAS wafer) in SS. The release profile of
NiQuitin® showed a more rapid drug release from the polymer matrix into SS than the wafers and
films. The in vitro release profiles of NiQuitin® and wafers and films showed a statistically significant
difference (p < 0.05).
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a f al es (i.e., si ilarity or iffere ce, res ecti ely) relati e to a selecte refere ce for latio ,
as s o i Table 3. The MAS film was chosen as a reference as it exhibited the lowest rate of
drug release.
Table 3. Si ilarity and difference factors for drug release profiles of optimized wafers and films
(a) between optimized wafers and film in SS and (b) between optimized wafers and film in PBS.
Optimized formulations (SS) Similarity factor (f2) Difference factor (f1)
MAS wafer 22.07 1597.71
MAS film Reference Reference
Non-MAS wafer 25.53 1362.02
(b)
Optimized formulations (PBS) Similarity factor (f2) Difference factor (f1)
MAS wafer 3.87 624.56
MAS film Reference Reference
Non-MAS wafer 6.82 535.57
Further, the drug dissolution profiles of all the formulated wafers and films in SS were compared
using NiQuitin® strips as the reference formulation and the results shown in Table 4.
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Table 4. Similarity (f 2) and difference factor (f 1) of optimized wafers and films compared to
NiQuitin® strips.
Optimized Formulations Similarity Factor (f2) Difference Factor (f1)
MAS wafer 28.58 41.43
MAS film 10.10 96.54
Non-MAS wafer 24.68 49.56
NiQuitin® Reference Reference
3.5. Drug Content (% Loading/Recovery) of Commercial Strips and Formulated Wafers and Films
Figure 7 shows the percentage drug in NIC-loaded commercial strips, formulated wafers,
and films. The commercial strips demonstrated the lowest NIC content (%), with 41 ± 5.10% NIC.
MAS wafer and film showed the highest NIC content, with 93 ± 0.40% and 92 ± 11.82% of NIC,
respectively. MAS was also confirmed to have a significant effect on NIC content as well as the
formulation technique as non-MAS film was demonstrated to have low NIC content in [32].
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3.6. Ex Vivo Buccal Permeation Studies (Porcine Buccal Tissue)
The cumulative permeation curves of formulated wafers (MAS and non-MAS wafers) and films
(MAS films) using porcine buccal tissues are shown in Figure 8, and the permeation flux (J) of the
formulations is shown in Table 5. NIC permeation in the formulated wafers and films demonstrated a
high cumulative permeation above 100 µg/cm2 with the wafers (MAS and non-MAS wafers), in general
demonstrating higher cumulative permeation than the films (MAS films).
The highest cumulative permeation and permeation flux (J) was shown in MAS wafers with the
maximum cumulative permeation of 432.30 ± 343.04 µg/cm2 within 4 h and permeation flux (J) of
108.08 ± 85.76 µg/cm2/h, while the lowest cumulative permeation and permeation flux (J) was shown
in MAS films with the maximum cumulative permeation of 169.30 ± 70.67 µg/cm2 within 4 h and
permeation flux (J) of 42.33 ± 17.67 µg/cm2/h.
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Table 5. Permeation flux (J) for NIC from optimized wafers and films through porcine mucosa
membrane and EpiOralTM tissue construct.
Formulation Flux (J) (µg/cm
2/h)
(mean± SD, n = 3)
Porcine tissue
MAS wafers 108.08 ± 85.76
MAS films 42.33 ± 17.67
Non-MAS wafers 69.22 ± 11.50
EpiOralTM tissue
MAS wafers 139.74 ± 22.29
MAS films 42.31 ± 5.22
Non-MAS wafers 140.55 ± 47.55
3.7. In Vitro Buccal Permeation Studies (EpiOralTM Buccal Tissue)
The cumulative permeation curves of the NIC released from wafers and films using EpiOralTM
buccal tissue are shown in Figure 9. The permeation flux (J) of NIC from wafers and films is also shown
in Table 5, with the permeation of NIC from wafers and films demonstrating a lag-time of 30 min.
The highest cumulative permeation within 4 h and permeation flux (J) was observed for wafers with
the maximum cumulative permeation of 562.22 ± 190.20 µg/cm2 (Non-MAS wafers) and permeation
flux (J) of 40.55 ± 47.55 µg/cm2/h. The MAS films demonstrated a lower cumulative permeation and
permeation flux within 4 h, with a maximum cumulative permeation of 169.234 ± 20.89 µg/cm2 and
permeation flux (J) of 42.31 ± 5.22 µg/cm2/h. EpiOralTM buccal tissues demonstrated a higher flux
than porcine buccal tissues.
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3.8. Permeation Correlation between In Vitro Porcine Buccal Tissue and EpiOralTM Engineered Buccal Tissue
The correlation between the cumulative permeation curve of NIC in wafers (i.e., MAS and
non-MAS wafers) and films using a porcine buccal tissue and EpiOralTM buccal engineered tissue
is shown in Figure 10. The results showed a positive correlation between wafers and films, with an
increase in cumulative permeation using EpiOralTM buccal tissue as the values for porcine buccal
tissue increased. The wafers generally showed higher regression than optimized films. MAS wafers
(Figure 10a) demonstrated the highest linear regression coefficient (0.935) while MAS films (Figure 10b)
demonstrated the least linear regression coefficient (0.675).
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3.9. Tissue Viability (MTT Assay) of EpiOralTM Tissues after Permeation Studies
Cell viability of EpiOralTM engineered buccal tissue following permeation studies of wafers and
films measured with MTT assay is shown in Figure 11. There was some reduction in the activity
of cell enzymes (mitochondrial succinate dehydrogenase) in all optimized wafer (i.e., MAS and
non-MAS wafers) and film (MAS films) formulations as there was a lower percentage of cell viability
in comparison to the negative non-treated control (100% viability). However, MAS films demonstrated
a high percentage cell viability (91 ± 13%) in comparison with wafers (MAS wafers; 86 ± 4% and
non-MAS wafers; 81 ± 21%).
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4. Discussion
The design of a buccal drug delivery system involves the successful application of the optimized
formulation to the buccal mucosa and the absorption of the drug either rapidly or in a controlled
manner over a stipulated period. The immediate microenvironment of the buccal mucosa region
plays a vital role in modulating the drug release with matrix swelling via hydration in the dissolution
medium, diffusion and erosion of the polymer matrix as the main mechanisms of a controlled release
formulation [41,42]. Human saliva therefore plays a major role in the release mechanism of a buccal
drug delivery system and it is vital in functional characterization of swelling and in vitro release
studies to consider the components i.e., presence of electrolytes such as sodium, calcium, potassium,
chloride, phosphate, bicarbonate, and magnesium.
The swelling results demonstrated a significantly higher swelling index in PBS than SS (p < 0.05)
especially for MAS wafer. This implies that the presence of electrolytes and predominantly negatively
charged mucin increases ionic interaction, which affected the swelling capacity of both optimized
wafers and films. The diffusion of PBS into MAS wafer can be attributed to electro-osmosis i.e.,
generation of an electric field by mobile ions in MAS (silicate, magnesium, and aluminium) with
accelerated flow, which induces high diffusivity of water molecules associated to these ions. This could
also explain why MAS wafers demonstrated higher swelling capacity than non-MAS wafers. However,
the presence of SS electrolytes reduced swelling capacity of the formulations by creating an ionic
pressure gradient. This excess pressure was introduced with the difference in concentrations of ions
in the formulation and in SS, which decreases the diffusion rate of SS into the formulations [43].
Furthermore, the ions and mucin present in SS compete for available ionic interaction with SA and
MAS in the MAS wafers and films and SA in optimized non-MAS wafer, hence reducing the rate of
hydration [26], and this eventually affects the rate of drug release from the swollen formulations.
The mucoadhesion of optimized wafers and films depends on various mechanisms of interaction
with the mucosa surface such as adsorption, wetting, diffusion and mechanical theories [44].
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The mucoadhesion in the presence of SS is slightly lower than in PBS, as previously reported [33]
suggesting that the presence of higher ionic interactions by components in SS such as sodium, calcium,
potassium, chloride, phosphate, bicarbonate, magnesium, and mucin could potentially interact with
the negatively charged SA and MAS group. This limited the ionic interaction as well as hydrogen
bonding with the mucin in the mucoadhesive model system used, because the ions and mucin present
in SS compete for bonding sites on the wafer and film polymeric matrices [45]. The high mucoadhesion
in the films compared to wafers could be attributed to adhesion based on liquid-to-solid affinity
(wetting theory), with the film’s large surface area playing a role in adhesion compared to optimized
wafers with lower total surface area and lesser contact with the mucosal surface because of the presence
of sponge-like pores. NiQuitin® strips also followed similar mucoadhesion profiles as MAS films,
since they are essentially a sheet-like formulation. However, the ionic effect on mucoadhesion from the
high concentration of charged components in SS is minimal, with only methyl acrylic acid–ethyl
acrylate copolymer (anionic) in NiQuitin® strips as a competing site for ionic interaction of SS
components compared to MAS film, which contained both SA (anionic polymer) and MAS (amphoteric
clay). In addition, the high hydration and swelling properties of methyl acrylic acid–ethyl acrylate
copolymer in NiQuitin® improved the diffusion properties, which encouraged chain entanglement
(diffusion theory of mucoadhesion).
One of the major challenges of dealing with free NIC base is its volatility, and NIC readily
evaporates in an unstable formulation. Based on the conditions used in the analysis of the formulated
wafers and film formulation, the low NIC content in NiQuitin® strips can be attributed to loss of NIC
over time, including during analysis. This suggests that the hydrogen bonding between the copolymer
and NIC was not stable enough to stabilize NIC within the commercial strips. The high NIC content in
MAS formulation can be attributed to strong ionic interaction between the negatively charged silicate
and the partially positively charged NIC in combination with hydrogen bonding between NIC and the
composite polymers in the formulation, hence stabilizing NIC in the formulation.
The in vitro drug release from optimized wafers and films significantly depends on the hydration,
which leads to swelling of the polymeric dosage form and eventual drug diffusion from the swollen
matrix [42]. As described above, the presence of electrolyte and mucin in SS caused a decrease in
the swelling capacity of the formulated wafers and films. These components create an ionic pressure
between the high concentration of charged components such as mucin and electrolyte in the SS and
the ions in the formulation. At the molecular level, this initial slow rate of release could be related
to ionic interactions between the drug, charged MAS, ionized alginate, and also competition with
the ions present in SS as compared to PBS. This type of effect, especially in the presence of SS, has
been reported in previous studies [26], where release was significantly slower in SS than in PBS. It is
possible that a longer period of release will show release of higher amounts of drug with eventual
matrix erosion, and this will need to be investigated in future studies. However, for the purposes of
buccal delivery, which was the main objective of the current study, the expected duration of release for
effective permeation and systemic action is usually 2 h, since most of the drug will eventually end up
in the saliva and be swallowed via the gastro-intestinal route.
The results of the in vitro drug release studies also demonstrated a similar trend to the swelling
data with a decrease in the release profile of wafers and films formulation in SS as compared to the
release profile in PBS. This implies that the presence of electrolytes and mucin slows down the release
rate from the formulations over time, hence avoiding dumping of NIC in the buccal mucosa region [26].
NiQuitin® strip is composed mainly of anionic copolymers i.e., methacrylic acid–ethyl acrylate
copolymer, and these copolymers contribute to the fast dissolution properties of NiQuitin® formulation
and the rapid release of NIC upon contact with saliva. Other components of NiQuitin® include triethyl
citrate used as a plasticizer, peppermint flavour and sucralose for taste masking, and sodium hydrogen
carbonate used as a buffer, all of which have high affinity for water. The swelling profile (% swelling
index against time) observed in NiQuitin® strips showed that the maximum swelling profile of
NiQuitin® strips was attained within 6 min of contact with the SS medium. Methyl acrylic acid–ethyl
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acrylate is an anionic based copolymer that responds to environmental pH. Anionic hydrogels are
usually ionized at higher pH above its pKa and become un-ionized below its pKa. The rapid dissolving
process of the copolymer used in NiQuitin® strips was activated with an increase in pH upon contact
with the SS solution by the neutralizing base (sodium hydrogen carbonate) which then creates an
osmotic swelling force in the copolymer network by the presence of hydroxyl ions [46]. The rapid
ingress of SS into the polymeric matric results in the eventual rapid erosion of the polymer matrix after
its optimum swelling capacity as observed in NiQuitin® swelling profile (Figure 6). However, in the
case of the MAS film and non-MAS wafer the swelling in SS was slower compared to the NiQuitin®.
Furthermore, the swelling appeared sustained in SS compared to PBS with the PBS profiles showing
decrease in % swelling with time, suggesting that the erosion effects on MAS film and non-MAS wafer
in SS was significantly lower than in NiQuitin®. This could explain the significant differences observed
in the eventual drug release in the first 2 h.
Compared with the HPMC–SA wafers and films, NiQuitin® strips showed a rapid release of
NIC in less than 30 min. This can be attributed to the rapid swelling of the strips in response to
environmental pH triggered by the neutralizing base in addition to the other highly water soluble
components (triethyl citrate and sucralose). However, the sharp decrease in swelling of the NiQuitin®
strips after the maximum swelling point at 6 min can be attributed to low concentration (8 mL of
medium in receiving chamber) of sodium hydrogen carbonate which impacts on osmotic swelling
force with a high ionic strength of the SS. The limitation of using the Franz diffusion cell to assess the
release of NIC from formulations such as NiQuitin® is that the product is designed to be placed on the
tongue and then pressed by the roof of the mouth. This increases the duration of drug release relative
to actual application as the pressure applied on the strip by the roof of the mouth will have increased
the disintegration of the polymer matrix and hence result in higher dissolution rate compared to the
experimental results obtained in this study. The Franz diffusion cell used in this project could not
model the pressure applied on the NiQuitin® both by the tongue and the roof of the mouth, but did
demonstrate the dissolution of NiQuitin® upon contact with SS. Using FDA guidelines in comparing
two or more dissolution profiles (similarity (f 2) and difference (f 1) factors), the wafers demonstrated a
difference in dissolution with NiQuitin® as the MAS wafers and non-MAS wafers showed f 2 similarity
factor <15 and f 1 difference factor <50, which could be related to the differences in micro- architecture.
This study also aimed to investigate NIC permeability when released from the wafers and films
using porcine and human engineered EpiOralTM buccal tissues as model buccal mucosa membranes.
The toxicity of the buccal cells was assessed as the mucoadhesive formulations were loaded with NIC,
which a known toxic compound at high doses [47]. The buccal route offers an ideal opportunity for
NIC delivery as it bypasses the NIC degradation (such as the hepatic first-pass effect) that occurs
when administered by the conventional oral route. NIC has the ability to more easily penetrate the
buccal route than the skin [21,48]. The buccal permeability of the wafers and films with different
physicochemical properties and attributes such as swelling and release properties was necessary, as it is
essential to achieve the required bioavailability for eventual therapeutic action. Furthermore, in order
to assess the reliability of the permeation results, both porcine and human engineered EpiOralTM
buccal tissues were utilized and compared.
The most important properties that affect the permeability of a drug compound through a tissue
membrane is its lipophilicity and molecular weight [49]. Lipophilicity is usually expressed in terms of
octanol–water partition coefficient (log P). NIC possesses a low log P value (1.17) and a low molecular
weight of 162.23 g/mol, which make it highly permeable via the buccal mucosa at physiological
pH (6.8), with un-ionized NIC permeating via the transcellular pathway, while ionized NIC permeates
via the paracellular route [18]. The permeation of NIC via porcine and EpiOralTM buccal tissue in
this study demonstrated a high flux value (between 40 µg/cm2/h and 150 µg/cm2/h) over a time
period of 4 h. Similar high flux values of NIC have been observed in previous studies using porcine
esophageal mucosa as a model membrane [50] and human skin [20]. Pongjanyakul and co-workers
demonstrated in their permeation studies a high permeation curve of NIC between 400 µg/cm2 and
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800 µg/cm2 within 8 h and also showed a decrease in film permeation rate as the MAS ratio in film
increased, which was a similar case to this study as NIC permeation decreased in the MAS films [50].
The use of porcine and EpiOralTM buccal tissue in these studies demonstrated a good correlation.
However, EpiOralTM buccal tissue demonstrated a higher permeation flux (J) than porcine buccal
tissue, which can be attributed to fatty tissues beneath the ex vivo porcine buccal mucosa tissue.
Hydration, swelling, and release rate of NIC from the formulations played a role on the permeation
flux across the porcine and EpiOralTM buccal tissues. Wafer formulations (MAS and non-MAS wafers)
showed a higher swelling index, which can be attributed to their high porosity, which allows rapid
ingress of dissolution medium into the polymer matrix [32]. The increased hydration and swelling
of wafers played a role in the release rate of NIC from the polymer matrix which influenced the
permeation flux in both porcine and EpiOralTM buccal tissue models with higher flux in comparison
to films. The increased NIC release from optimized wafers allows a higher concentration diffusion
gradient towards absorption across the buccal membrane compared to the films. Film formulations
(MAS films), on the other hand, demonstrated a lower permeation flux in both porcine and EpiOralTM
buccal tissue models which can be attributed to lower rates of hydration, swelling and release [32,51].
The diffusion of fluid into film formulation is relatively slow owing to the continuous polymeric
sheet and absence of pores which therefore affects the hydration and swelling of the formulations
and subsequent release rate of NIC from the swollen gels with low concentration diffusion gradient
towards absorption across the buccal membrane. This implies that optimized wafers can provide a
more rapid action while optimized films can provide a prolonged action.
MTT was utilized to assess the tissue viability of EpiOralTM after contact with the optimized
wafers and films. The assay investigates the reduction of yellow MTT to an insoluble purple formazan
predominantly by enzymes (succinate dehydrogenase) found in the mitochondria of viable cells [52–54].
The MTT assay demonstrated some level of cytotoxicity by NIC, with the non-viable cell’s inability to
reduce yellow MTT to purple formazan. NIC has been reported by Chang and co-workers to suppress
the growth of periodontal ligament fibroblast (PDLF) as well as inhibit cell proliferation and decrease
protein synthesis, with an increase in NIC concentration [47]. NIC-induced cytotoxicity was shown
in the current study, with optimized wafers demonstrating 14% non-viable cells in MAS wafers and
19% non-viable cells in non-MAS wafers; however, a lower percentage of non-viable cells (8%) was
shown in MAS films. The increase in NIC-induced cytotoxicity in optimized wafer formulations was
as a result of increased hydration and swelling of wafers, which resulted in more rapid release of
NIC from the polymeric matrix. The film formulation, however, demonstrated slow hydration and
swelling, leading to slow NIC release with lower concentration diffusion gradient thereby resulting
in lower numbers of non-viable cells in EpiOralTM buccal tissue. However, in general, the results of
cell viability (MTT) assay for both the wafers and films demonstrated that the formulations can be
considered safe to use, since the percentage of viable cells was more than 70% after exposure, which is
the acceptable international standard [55,56].
5. Conclusions
HPMC–SA based wafers and films were analysed for swelling and NIC release properties using
SS as medium to demonstrate the effect of the constituents of SS such as electrolytes and mucin on
formulation performance. The formulations demonstrated reduced swelling properties in SS compared
to PBS, attributed to the ionic pressure created by the high concentration of ions and mucin present in
SS. The drug release profile of the optimized formulations demonstrated a slow release profile within
30 min, which correlated directly with the swelling profile. On the other hand, the swelling profile of
NiQuitin® strips demonstrated a rapid swelling within 6 min and also a higher swelling compared
to the HPMC–SA based wafers and films but eroded rapidly after reaching its optimum swelling
capacity. NIC content in the wafers and films also demonstrated higher content (recovery) of NIC in
comparison to NiQuitin® strips, attributed to the ionic interaction between the MAS and NIC as well
as hydrogen bonding of NIC to the SA within the composite formulations which stabilized the drug
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within the wafers and films. Furthermore, the rapid swelling rate of NiQuitin® strips was directly
related to its rapid release of NIC from the polymer matrix in comparison with HPMC–SA wafers and
films. NIC released from the wafers demonstrated a higher permeation flux than the corresponding
films for both porcine and EpiOralTM buccal tissue, attributed to the differences in functional physical
(hydration, swelling and release) properties of optimized wafers and films. A good correlation was
achieved between NIC cumulative permeation in porcine and EpiOralTM buccal tissues, with wafers
(MAS wafers) showing the highest correlation coefficient. As a result of the high concentration of
NIC released from the wafers, the percentage of viable cells in EpiOralTM buccal tissue was reduced
the most in wafers compared to the films. However, the HPMC–SA based wafers and films can be
considered safe, as the percentage of viable cells was >70%.
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